Details
Stereochemistry | ABSOLUTE |
Molecular Formula | 2C22H30N6OS.5BrH |
Molecular Weight | 1257.716 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Br.Br.Br.Br.Br.[H][C@]1(CN[C@@]([H])(C1)C(=O)N2CCSC2)N3CCN(CC3)C4=CC(C)=NN4C5=CC=CC=C5.[H][C@]6(CN[C@@]([H])(C6)C(=O)N7CCSC7)N8CCN(CC8)C9=CC(C)=NN9C%10=CC=CC=C%10
InChI
InChIKey=LUXIOMHUGCXFIU-MAYGPZJUSA-N
InChI=1S/2C22H30N6OS.5BrH/c2*1-17-13-21(28(24-17)18-5-3-2-4-6-18)26-9-7-25(8-10-26)19-14-20(23-15-19)22(29)27-11-12-30-16-27;;;;;/h2*2-6,13,19-20,23H,7-12,14-16H2,1H3;5*1H/t2*19-,20-;;;;;/m00...../s1
Molecular Formula | C22H30N6OS |
Molecular Weight | 426.578 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | BrH |
Molecular Weight | 80.912 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/23671395Curator's Comment: description was created based on several sources, including https://www.pmda.go.jp/files/000153594.pdf
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23671395
Curator's Comment: description was created based on several sources, including https://www.pmda.go.jp/files/000153594.pdf
Teneligliptin is a DPP IV inhibitor which was developed by Mitsubishi Tanabe Pharma and now is used for the treatment of type 2 diabetes mellitus in Asia under the name Tenelia.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL284 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23671395 |
0.889 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | TENELIA Approved UseType 2 diabetes mellitus. Launch Date2012 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.pmda.go.jp/files/000153594.pdf
The usual adult dosage is 20 mg of teneligliptin administered orally once daily. If efficacy is insufficient, the dose may be increased up to 40 mg once daily while closely monitoring the clinical course.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27530507
Human umbilical vein endothelial cells were cultured under normal (5 mmol/L) or high glucose level (25 mmol/L) during 21 days, or at high glucose during 14 days followed by 7 days at normal glucose, to reproduce the high-metabolic memory state. At this time, different concentrations of teneligliptin (0.1, 1.0 and 3.0 umol/L) were added to cells. Teneligliptin was shown to protect human umbilical vein endothelial cells from oxidative stress.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 18:19:58 GMT 2023
by
admin
on
Fri Dec 15 18:19:58 GMT 2023
|
Record UNII |
556RZT8JPF
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
906093-29-6
Created by
admin on Fri Dec 15 18:19:58 GMT 2023 , Edited by admin on Fri Dec 15 18:19:58 GMT 2023
|
PRIMARY | |||
|
556RZT8JPF
Created by
admin on Fri Dec 15 18:19:58 GMT 2023 , Edited by admin on Fri Dec 15 18:19:58 GMT 2023
|
PRIMARY | |||
|
11996485
Created by
admin on Fri Dec 15 18:19:58 GMT 2023 , Edited by admin on Fri Dec 15 18:19:58 GMT 2023
|
PRIMARY | |||
|
DTXSID90238219
Created by
admin on Fri Dec 15 18:19:58 GMT 2023 , Edited by admin on Fri Dec 15 18:19:58 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SOLVATE->ANHYDROUS | |||
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |